Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Li Ning Company's controlling vehicle, Viva China Holdings, has been buying aggressively. Filings reported in early September show it spent over $145m across five separate open-market purchases between August 27 and September 3. The largest single transaction, filed on September 2, was worth nearly $67m. That kind of sustained, multi-day accumulation from a board-linked holding company is among the strongest signals in the insider dataset.
The contrast with CEO-level activity elsewhere is stark. The founder and CEO of ARGX argenx SE filed a $21m open-market sale on September 5, covering 20,000 shares traded on September 3. Meanwhile, Zetrix AI Berhad's founder-CEO Wong Thean Soon disclosed a string of sales totalling more than $45m across late August and early September.
At NMIH NMI Holdings, CEO Adam Pollitzer filed a $7.7m sale on September 4. No 10b5-1 plan flag was visible in the data, making this a discretionary trade worth watching.
On the institutional activism front, Fosun Pharma trimmed its stake in Gland Pharma with two disclosed sell transactions worth a combined $296m, while BlackRock reported sizable reductions in Kingdee International Software.
Note: US open-market Form 4 data from SEC EDGAR was unavailable in this environment; the article draws on the vendor insider dataset, which covers non-US markets most fully. Fresh US Schedule 13D filings could not be retrieved.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
